European standard clinical practice recommendations for paediatric high-grade gliomas

Elwira Szychot; Géraldine Giraud; Darren Hargrave; Dannis van Vuurden; Jacques Grill; Veronica Biassoni; Maura Massimo; André O. Von Büren; Rejin Kebudi; Maria João Gil-da-Costa; Sophie Veldhuijzen van Zanten; Simon Bailey; Michael Karremann; Stephanie Bolle; Thankamma Ajithkumar; Mechthild Krause; Yasmin Lassen-Ramshad; Geert Janssens; Giovanni Morana; Ulrike Löbel; Shivaram Avula; Brigitte Bison; Maarten Lequin; Kristian Aquilina; Ulrich Thomale; Pelle Nilsson; Sami Bui Quy Abu Hamdeh; Torsten Pietsch; Pascale Varlet; Thomas S. Jacques; Pieter Wesseling; David Jones; Uri Tabori; Anirban Das; David Mulligan; Francesca Kozmann; Christof M. Kramm

doi:10.1016/j.ejcped.2024.100210

European standard clinical practice recommendations for paediatric high-grade gliomas

Elwira Szychot^*, Géraldine Giraud, Darren Hargrave, Dannis van Vuurden, Jacques Grill, Veronica Biassoni, Maura Massimo, André O. Von Büren, Rejin Kebudi, Maria João Gil-da-Costa, Sophie Veldhuijzen van Zanten, Simon Bailey, Michael Karremann, Stephanie Bolle, Thankamma Ajithkumar, Mechthild Krause, Yasmin Lassen-Ramshad, Geert Janssens, Giovanni Morana, Ulrike LöbelShivaram Avula, Brigitte Bison, Maarten Lequin, Kristian Aquilina, Ulrich Thomale, Pelle Nilsson, Sami Bui Quy Abu Hamdeh, Torsten Pietsch, Pascale Varlet, Thomas S. Jacques, Pieter Wesseling, David Jones, Uri Tabori, Anirban Das, David Mulligan, Francesca Kozmann, Christof M. Kramm

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Paediatric high-grade gliomas (pedHGGs) are highly invasive brain tumours accounting for approximately 15 % of all central nervous system (CNS) tumours in children and adolescents. The outcome for these tumours is generally poor with 5-year survival rates of less than 20 %. Despite improved biological insights into pedHGGs and the promise of more effective therapies, little progress has been made in the effective treatment and the outcome of these tumours over the last four decades. Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. This guideline was written by members of the SIOPE HGG Working Group as part of the European Standard Clinical Practice (ESCP) Project. The guideline aims to integrate available evidence-based and expert opinion-based information to assist healthcare professionals in the management of pedHGGs and in an attempt to provide equity in healthcare reflecting the varying resources of each European country.

Original language	English
Article number	100210
Journal	EJC Paediatric Oncology
Volume	5
DOIs	https://doi.org/10.1016/j.ejcped.2024.100210
Publication status	Published - Jun 2025
Externally published	Yes

Keywords

Children
High-grade glioma
Practice recommendations

Access to Document

10.1016/j.ejcped.2024.100210Licence: CC BY

Cite this

Szychot, E., Giraud, G., Hargrave, D., van Vuurden, D., Grill, J., Biassoni, V., Massimo, M., Von Büren, A. O., Kebudi, R., Gil-da-Costa, M. J., van Zanten, S. V., Bailey, S., Karremann, M., Bolle, S., Ajithkumar, T., Krause, M., Lassen-Ramshad, Y., Janssens, G., Morana, G., ... Kramm, C. M. (2025). European standard clinical practice recommendations for paediatric high-grade gliomas. EJC Paediatric Oncology, 5, Article 100210. https://doi.org/10.1016/j.ejcped.2024.100210

@article{bd2a9d4e725a49d7b5cc3ae08140d9e1,

title = "European standard clinical practice recommendations for paediatric high-grade gliomas",

abstract = "Paediatric high-grade gliomas (pedHGGs) are highly invasive brain tumours accounting for approximately 15 % of all central nervous system (CNS) tumours in children and adolescents. The outcome for these tumours is generally poor with 5-year survival rates of less than 20 %. Despite improved biological insights into pedHGGs and the promise of more effective therapies, little progress has been made in the effective treatment and the outcome of these tumours over the last four decades. Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. This guideline was written by members of the SIOPE HGG Working Group as part of the European Standard Clinical Practice (ESCP) Project. The guideline aims to integrate available evidence-based and expert opinion-based information to assist healthcare professionals in the management of pedHGGs and in an attempt to provide equity in healthcare reflecting the varying resources of each European country.",

keywords = "Children, High-grade glioma, Practice recommendations",

author = "Elwira Szychot and G{\'e}raldine Giraud and Darren Hargrave and {van Vuurden}, Dannis and Jacques Grill and Veronica Biassoni and Maura Massimo and {Von B{\"u}ren}, {Andr{\'e} O.} and Rejin Kebudi and Gil-da-Costa, {Maria Jo{\~a}o} and {van Zanten}, {Sophie Veldhuijzen} and Simon Bailey and Michael Karremann and Stephanie Bolle and Thankamma Ajithkumar and Mechthild Krause and Yasmin Lassen-Ramshad and Geert Janssens and Giovanni Morana and Ulrike L{\"o}bel and Shivaram Avula and Brigitte Bison and Maarten Lequin and Kristian Aquilina and Ulrich Thomale and Pelle Nilsson and Hamdeh, {Sami Bui Quy Abu} and Torsten Pietsch and Pascale Varlet and Jacques, {Thomas S.} and Pieter Wesseling and David Jones and Uri Tabori and Anirban Das and David Mulligan and Francesca Kozmann and Kramm, {Christof M.}",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = jun,

doi = "10.1016/j.ejcped.2024.100210",

language = "English",

volume = "5",

journal = "EJC Paediatric Oncology",

issn = "2772-610X",

publisher = "Elsevier",

}

Szychot, E, Giraud, G, Hargrave, D, van Vuurden, D, Grill, J, Biassoni, V, Massimo, M, Von Büren, AO, Kebudi, R, Gil-da-Costa, MJ, van Zanten, SV, Bailey, S, Karremann, M, Bolle, S, Ajithkumar, T, Krause, M, Lassen-Ramshad, Y, Janssens, G, Morana, G, Löbel, U, Avula, S, Bison, B, Lequin, M, Aquilina, K, Thomale, U, Nilsson, P, Hamdeh, SBQA, Pietsch, T, Varlet, P, Jacques, TS, Wesseling, P, Jones, D, Tabori, U, Das, A, Mulligan, D, Kozmann, F & Kramm, CM 2025, 'European standard clinical practice recommendations for paediatric high-grade gliomas', EJC Paediatric Oncology, vol. 5, 100210. https://doi.org/10.1016/j.ejcped.2024.100210

TY - JOUR

T1 - European standard clinical practice recommendations for paediatric high-grade gliomas

AU - Szychot, Elwira

AU - Giraud, Géraldine

AU - Hargrave, Darren

AU - van Vuurden, Dannis

AU - Grill, Jacques

AU - Biassoni, Veronica

AU - Massimo, Maura

AU - Von Büren, André O.

AU - Kebudi, Rejin

AU - Gil-da-Costa, Maria João

AU - van Zanten, Sophie Veldhuijzen

AU - Bailey, Simon

AU - Karremann, Michael

AU - Bolle, Stephanie

AU - Ajithkumar, Thankamma

AU - Krause, Mechthild

AU - Lassen-Ramshad, Yasmin

AU - Janssens, Geert

AU - Morana, Giovanni

AU - Löbel, Ulrike

AU - Avula, Shivaram

AU - Bison, Brigitte

AU - Lequin, Maarten

AU - Aquilina, Kristian

AU - Thomale, Ulrich

AU - Nilsson, Pelle

AU - Hamdeh, Sami Bui Quy Abu

AU - Pietsch, Torsten

AU - Varlet, Pascale

AU - Jacques, Thomas S.

AU - Wesseling, Pieter

AU - Jones, David

AU - Tabori, Uri

AU - Das, Anirban

AU - Mulligan, David

AU - Kozmann, Francesca

AU - Kramm, Christof M.

PY - 2025/6

Y1 - 2025/6

N2 - Paediatric high-grade gliomas (pedHGGs) are highly invasive brain tumours accounting for approximately 15 % of all central nervous system (CNS) tumours in children and adolescents. The outcome for these tumours is generally poor with 5-year survival rates of less than 20 %. Despite improved biological insights into pedHGGs and the promise of more effective therapies, little progress has been made in the effective treatment and the outcome of these tumours over the last four decades. Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. This guideline was written by members of the SIOPE HGG Working Group as part of the European Standard Clinical Practice (ESCP) Project. The guideline aims to integrate available evidence-based and expert opinion-based information to assist healthcare professionals in the management of pedHGGs and in an attempt to provide equity in healthcare reflecting the varying resources of each European country.

AB - Paediatric high-grade gliomas (pedHGGs) are highly invasive brain tumours accounting for approximately 15 % of all central nervous system (CNS) tumours in children and adolescents. The outcome for these tumours is generally poor with 5-year survival rates of less than 20 %. Despite improved biological insights into pedHGGs and the promise of more effective therapies, little progress has been made in the effective treatment and the outcome of these tumours over the last four decades. Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. This guideline was written by members of the SIOPE HGG Working Group as part of the European Standard Clinical Practice (ESCP) Project. The guideline aims to integrate available evidence-based and expert opinion-based information to assist healthcare professionals in the management of pedHGGs and in an attempt to provide equity in healthcare reflecting the varying resources of each European country.

KW - Children

KW - High-grade glioma

KW - Practice recommendations

UR - http://www.scopus.com/inward/record.url?scp=85213834943&partnerID=8YFLogxK

U2 - 10.1016/j.ejcped.2024.100210

DO - 10.1016/j.ejcped.2024.100210

M3 - Article

AN - SCOPUS:85213834943

SN - 2772-610X

VL - 5

JO - EJC Paediatric Oncology

JF - EJC Paediatric Oncology

M1 - 100210

ER -

European standard clinical practice recommendations for paediatric high-grade gliomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this